BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon has filed the quarterly Monitoring Agency Report from India Ratings & Research on the use of proceeds from its Qualified Institutions Placement (QIP) conducted in June 2025. The QIP raised ₹45,000 million (₹4,500 crore) through the issue of 13.63 crore equity shares at around ₹330 each. During the quarter, the company utilized ₹16,985.72 million, mainly ₹16,980.46 million towards buying back optionally convertible debentures of subsidiary Biocon Biologics from Goldman Sachs AIF schemes. Repayment of borrowings (₹27,150 million allocated), general corporate purposes (₹169.54 million), and issue expenses (₹5.26 million used out of ₹700 million) saw no deployment this quarter. The remaining ₹28,014.28 million is parked in money market mutual funds and bank accounts. The agency confirmed no deviation from the stated objects, no delays, and no adverse events affecting viability.
The report is largely procedural and confirms Biocon is deploying QIP funds as promised to investors, with no diversions. The bulk of the ₹4,500 crore raise is still unutilized and parked in liquid funds, meaning future quarters will show more meaningful progress, especially on the debt repayment leg. This is a neutral-to-mildly positive signal on corporate governance and capital discipline.